bluebird bio to Present New Data from LentiGlobinTM Clinical Studies at European Hematology Association (EHA) Annual Meeting Read more about bluebird bio to Present New Data from LentiGlobinTM Clinical Studies at European Hematology Association (EHA) Annual Meeting
bluebird bio to Present Updated Clinical Results from Novel Anti-BCMA CAR T Cell Therapy bb2121 at American Society of Clinical Oncology (ASCO) Annual Meeting Read more about bluebird bio to Present Updated Clinical Results from Novel Anti-BCMA CAR T Cell Therapy bb2121 at American Society of Clinical Oncology (ASCO) Annual Meeting
bluebird bio Reports First Quarter 2017 Financial Results and Recent Operational Progress Read more about bluebird bio Reports First Quarter 2017 Financial Results and Recent Operational Progress
bluebird bio Enters Lentiviral Vector Patent License Agreement with GlaxoSmithKline for Commercialization of Gene Therapies Read more about bluebird bio Enters Lentiviral Vector Patent License Agreement with GlaxoSmithKline for Commercialization of Gene Therapies
bluebird bio Licenses Lentiviral Vector Patent Rights for Development and Commercialization of Cell Therapies Read more about bluebird bio Licenses Lentiviral Vector Patent Rights for Development and Commercialization of Cell Therapies
bluebird bio to Present at Upcoming Investor Conferences Read more about bluebird bio to Present at Upcoming Investor Conferences
bluebird bio Appoints New Senior Manufacturing and Corporate Development Executives Read more about bluebird bio Appoints New Senior Manufacturing and Corporate Development Executives
bluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene Therapy in The New England Journal of Medicine Read more about bluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene Therapy in The New England Journal of Medicine
bluebird bio to Present at Two Investor Conferences in March Read more about bluebird bio to Present at Two Investor Conferences in March
bluebird bio Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Progress Read more about bluebird bio Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Progress